Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 23092175)


Histone deacetylase inhibitor MC1293 induces latent HIV-1 reactivation by histone modification in vitro latency cell lines.

Qu X, Ying H, Wang X, Kong C, Zhou X, Wang P, Zhu H.

Curr HIV Res. 2013 Jan;11(1):24-9.


Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB.

Ying H, Zhang Y, Zhou X, Qu X, Wang P, Liu S, Lu D, Zhu H.

PLoS One. 2012;7(11):e48832. doi: 10.1371/journal.pone.0048832. Epub 2012 Nov 15.


Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Yin H, Zhang Y, Zhou X, Zhu H.

Mol Biol Rep. 2011 Nov;38(8):5071-8. doi: 10.1007/s11033-010-0653-6. Epub 2010 Dec 23.


HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells.

Lin S, Zhang Y, Ying H, Zhu H.

Curr HIV Res. 2011 Jun;9(4):202-8. doi: 10.2174/157016211796320333.


The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response.

Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I.

FEBS Lett. 2011 Nov 16;585(22):3549-54. doi: 10.1016/j.febslet.2011.10.018. Epub 2011 Oct 19.


Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.

Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM.

AIDS. 2009 Sep 10;23(14):1799-806. doi: 10.1097/QAD.0b013e32832ec1dc.


Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression.

Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, Ochiai K, Okamoto T.

FEBS Lett. 2011 Apr 6;585(7):1103-11. doi: 10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12.


The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.


Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.

Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, Isomura H, Kanda T, Tsurumi T.

J Virol. 2012 May;86(9):4752-61. doi: 10.1128/JVI.06768-11. Epub 2012 Feb 22.


Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.

Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N.

J Biol Chem. 2011 Jun 24;286(25):22211-8. doi: 10.1074/jbc.M110.180224. Epub 2011 Apr 29.


Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.

Quivy V, De Walque S, Van Lint C.

Subcell Biochem. 2007;41:371-96. Review.


Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies.

Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, Berkhout B, Castellano R, de Launoit Y, Burny A, Piette J, Bours V, Van Lint C.

J Virol. 2002 Nov;76(21):11091-103.


NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.

Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC.

EMBO J. 2006 Jan 11;25(1):139-49. Epub 2005 Dec 1.


Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.


Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Lusic M, Marcello A, Cereseto A, Giacca M.

EMBO J. 2003 Dec 15;22(24):6550-61.


Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.

Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J.

J Virol. 2011 Sep;85(17):9078-89. doi: 10.1128/JVI.00836-11. Epub 2011 Jun 29.


Prostratin antagonizes HIV latency by activating NF-kappaB.

Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC.

J Biol Chem. 2004 Oct 1;279(40):42008-17. Epub 2004 Jul 28.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk